symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CDXI,0.0002,0.246456,12,883,0,2.0E-4-0.43,0,"Cardax, Inc.",USD,0001544238,US14141D2018,14141D201,Other OTC,PNK,Biotechnology,https://www.cardaxpharma.com,"Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.",Mr. David G. Watumull,Healthcare,US,10,808 457 1400,2800 Woodlawn Drive,Honolulu,HI,96822,4.07528,5.07528,https://financialmodelingprep.com/image-stock/CDXI.png,2013-03-06,False,False,False,False,False
